Evidence map›Paper›PMID 38533186›Full record

ArticleFrontiers in toxicology2024

Evaluation of the applicability of GARDskin to predict skin sensitizers in extracts from medical device materials.

Rose-Marie Jenvert, Olivia Larne, Angelica Johansson, Mattias Berglin, Emma Pedersen, Henrik Johansson

Open access · goldAbstract read
In one paragraph

Article in Frontiers in toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rose-Marie JenvertSenzaGen AB, Lund, Sweden.
Olivia LarneSenzaGen AB, Lund, Sweden.
Angelica JohanssonSenzaGen AB, Lund, Sweden.
Mattias BerglinRISE Research Institutes of Sweden AB, Borås, Sweden.
Emma PedersenRISE Research Institutes of Sweden AB, Borås, Sweden.
Henrik JohanssonSenzaGen AB, Lund, Sweden.
RISE Research Institutes of Sweden · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biocompatibility testing of medical devices is governed by the ISO 10993 series of standards and includes evaluation of skin sensitization potential of the final product. A majority of all medical devices are tested using

Indexed as

biocompatibilitygardin vitroISO 10993medical deviceNAMsskin sensitization

Identifiers

PMID38533186
PMCPMC10964320
OpenAlexW4392715594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.